Kineta Past Earnings Performance
Past criteria checks 0/6
Kineta's earnings have been declining at an average annual rate of -48.6%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 34.1% per year.
Key information
-48.6%
Earnings growth rate
-49.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -34.1% |
| Return on equity | -460.2% |
| Net Margin | -259.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kineta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -14 | 12 | 0 |
| 30 Sep 23 | 6 | -58 | 13 | 16 |
| 30 Jun 23 | 6 | -59 | 13 | 14 |
| 31 Mar 23 | 2 | -65 | 10 | 16 |
| 31 Dec 22 | 2 | -63 | 9 | 0 |
| 30 Sep 22 | 3 | -20 | 7 | 4 |
| 30 Jun 22 | 5 | -17 | 6 | 15 |
| 31 Mar 22 | 7 | -14 | 5 | 12 |
| 31 Dec 21 | 9 | -12 | 5 | 16 |
| 31 Dec 20 | 10 | -8 | 4 | 9 |
Quality Earnings: KA is currently unprofitable.
Growing Profit Margin: KA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: KA has a negative Return on Equity (-460.15%), as it is currently unprofitable.